Tag: pharmaceuticals

  • Patent Awarded for Cell Life, Protein Production Technology

    Immunomedics Inc., a pharmaceutical company in Morris Plains, New Jersey has been granted a U.S. patent for its discoveries that extend the lifetime of cell lines and improve production of therapeutic proteins. Patent number 8,076,140 — “Mammalian cell lines for increasing longevity and protein yield from a cell culture” — was issued yesterday by the…

  • Biotech Secures $20 Million in Early Stage Financing

    ImmusanT Inc. in Cambridge, Massachusetts has received $20 million in early stage financing to develop its therapy and diagnostic tools  for celiac disease. The funds from venture capital firm Vatera Healthcare Partners LLC are expected to support further research and development of the company’s Nexvax2 therapeutics and diagnostics to a proof-of-concept demonstration. ImmusanT’s Nexvax2 therapeutic…

  • Treatment Developed for Immune Systems of Chemo Patients

    Researchers from University of Pennsylvania in Philadelphia have devised a treatment to repair the immune systems of leukemia patients undergoing chemotherapy using the patients’ own infection-fighting cells. The findings from the team that included participants from M.D. Anderson Cancer Center and Baylor College of Medicine in Houston were presented yesterday at the annual meeting of…

  • Venture Fund Raises $50M for Life Science Investments

    Forbion Capital Partners in the Netherlands says it is closing a new $50 million fund for investing in life science start-up companies nearing liquidity. The company’s second FCF 1 Co-Investment Fund plans to invest additional capital into its current portfolio of life science and biomedical technology companies. Forbion specializes in backing new businesses with late…

  • Genome Institute to Fund Research on Rare Diseases, Medical Care

    Funding announced by the National Human Genome Research Institute (NHGRI), part of National Institutes of Health, will support new research on rare inherited diseases, informatics tools, and use of genomic data in medical care delivery. The four-year, $416 million plan also continues funding for current initiatives on large-scale genomic sequencing production. NHGRI plans to award…

  • UC San Francisco, GE to Partner on Cord Blood Research

    University of California at San Francisco and and GE Healthcare are collaborating on an R&D project to help overcome the lack of blood-forming stem cells available to patients suffering from several life-threatening diseases. The three-year, $841,000 project aims to make better use of umbilical cord blood gathered at the birth of a baby, which is…

  • PhRMA: 88 HIV/AIDS Meds in Development at U.S. Companies

    A report by Pharmaceutical Research and Manufacturers of America (PhRMA) says U.S. biopharmaceutical companies are testing 88 medicines and vaccines to treat or prevent HIV/AIDS and related conditions. The report, issued on World AIDS Day (1 December 2011), also lists 36 currently approved medications for HIV infection and AIDS. According to PhRMA’s report, more than…

  • Trial Shows Safety of Engineered Gene Therapy

    In an early-stage clinical trial, researchers at University of North Carolina in Chapel Hill have demonstrated the safety of creating a genetically-engineered virus to treat a form of muscular dystrophy. The findings of pharmacologist Jude Samulski (pictured left) and colleagues are reported online in the journal Molecular Therapy; paid subscription required. With gene therapy, a…

  • Patent Awarded for Synthetic Canine Antimicrobial Peptide

    Kansas State University in Manhattan says a team of its researchers has received a U.S. patent for their discovery of a synthetic peptide that helps dogs better fight pathogens, such as bacteria, viruses and fungi. The patent, “Antimicrobial Cathelicidin Peptides” was awarded by the U.S. Patent and Trademark Office to K-State nutritionist Tonatiuh Melgarejo, immunophysiologist…

  • Fox Foundation to Fund Parkinson’s Drug Candidate Studies

    Civitas Therapeutics Inc., a pharmaceutical company in Chelsea, Massachusetts, received a grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the company’s lead drug candidate CVT-301. The amount of the grant to fund clinical development of the drug was not disclosed. Parkinson’s disease occurs when the nerve cells in the brain…